Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys' Q1 Revenues Inch up 1 Percent

NEW YORK (GenomeWeb News) – Accelrys reported after the close of the market on Thursday that its fiscal 2009 first-quarter revenues ticked up 1 percent, while its profit dipped on restructuring charges.
 
The San Diego-based bioinformatics firm generated revenues of $20.3 million for the three-month period ended June 30, compared to $20.1 million in the first quarter of 2008. The firm said in a statement that its revenue gains were “partially offset by reduced revenue from deemphasized products.”
 
Accelrys’ net income dropped to $86,000, or $.00 per share, compared to a profit of $1.4 million, or $.05 per share, in the first quarter of 2008. The firm’s earnings were hit by $842,000 in restructuring charges compared with $25,000 for similar charges a year earlier.
 
Acclery’s R&D expenses were virtually flat year over year at $4.3 million, while its SG&A costs increased slightly to $11.6 million from $11.4 million.
 
The company finished the quarter with $74.9 million in cash and marketable securities.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.